<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22573">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812953</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01832-47</org_study_id>
    <nct_id>NCT02812953</nct_id>
  </id_info>
  <brief_title>Biological Collection and Registry of Patients Who Will Have a TAVR (Transcatheter Aortic Valve Replacement) Intervention</brief_title>
  <acronym>BIO TAVI</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Action, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Action, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A sample of plasma and whole blood will be obtained at 3 time points (pre-procedural, early
      post-procedural and at hospital discharge). Test for platelet reactivity (LTA, light
      transmittance aggregometry and Elisa PRI, Platelet reactivity index) and for multimeric VWF
      (von Willebrand factor) analyses will be performed at the time of blood sampling. Aliquots
      of plasma will be stored and frozen for further analyses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two major objectives:

        -  To correlate changes in VWF and platelet reactivity after TAVR with clinical outcomes

        -  To correlate changes in VWF and platelet reactivity with antithrombotic regimens after
           TAVR (direct anticoagulants apixaban versus standard of care, ie Vitamin K antagonist
           or antiplatelet therapy).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>12 months</time_frame>
    <description>stroke/transient ischemic attack; acute coronary syndrome; hospitalization for cardiac insufficiency, cardiovascular or unexplained deaths will be collected at 12 month by phone contact with the patient or his/her relatives or his/her treating physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Serious bleeding event (BLEED II or more) will be collected at 12 month by phone contact with the patient or his/her relatives or his/her treating physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean pressure transprosthetic gradient</measure>
    <time_frame>within ten days after valve replacement</time_frame>
    <description>value of the mean pressure transprosthetic gradient after TAVR procedure will be assessed by TTE (transthoracic echography) or TOE (transesophageal echography)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      platelet poor plasma for von Willebrandt Factor further evaluation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient undergoing TAVR
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient undergoing TAVR intervention

          -  agreement given

        Exclusion Criteria:

          -  severe thrombopenia ( &lt;40.10^9/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Philippe COLLET, MD, PhD</last_name>
    <phone>+33142162962</phone>
    <email>jean-philippe.collet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Brugier, PhD</last_name>
    <phone>+33142162918</phone>
    <email>delphine.brugier-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 24, 2016</lastchanged_date>
  <firstreceived_date>May 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
